Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2016 - 2026)

Corvus Pharmaceuticals' Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $29000.0 for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 31.82% to $29000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $112000.0 through Mar 2026, up 33.33% year-over-year, with the annual reading at $105000.0 for FY2025, 23.53% up from the prior year.
  • Depreciation & Amortization (CF) came in at $29000.0 for Q1 2026, up from $26000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $94000.0 in Q3 2022 to a low of $20000.0 in Q4 2024.
  • The 5-year median for Depreciation & Amortization (CF) is $29000.0 (2025), against an average of $43352.9.
  • Year-over-year, Depreciation & Amortization (CF) crashed 70.21% in 2023 and then surged 38.1% in 2025.
  • Corvus Pharmaceuticals' Depreciation & Amortization (CF) stood at $94000.0 in 2022, then plummeted by 70.21% to $28000.0 in 2023, then dropped by 28.57% to $20000.0 in 2024, then increased by 30.0% to $26000.0 in 2025, then increased by 11.54% to $29000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Depreciation & Amortization (CF) are $29000.0 (Q1 2026), $26000.0 (Q4 2025), and $28000.0 (Q3 2025).